Table 1

Biologic and targeted synthetic disease-modifying antirheumatic drugs included in the network meta-analyses (all agents administered as per EU labelling)

TreatmentTargetYear of EMA market
authorisation for PsA
IL antagonists
Ixekizumab 80 mg SC Q2WIL-17A2018
Ixekizumab 80 mg SC Q4W
Secukinumab 150 mg SC Q4WIL-17A2015
Secukinumab 300 mg SC Q4W
Ustekinumab 45 mg SC Q12WIL-12-p40 and IL-23-p402013
Ustekinumab 90 mg SC Q12W
TNF-α inhibitors
Adalimumab 40 mg SC Q2WTNF-α2005
Certolizumab pegol 200 mg SC Q2W/400 mg SC Q4W2013
Etanercept 25 mg SC BIW/50 mg SC Q1W2003
Golimumab 50 mg SC Q4W2009
Infliximab 5 mg/kg IV Q8W2005
Abatacept 10 mg/kg IV Q4WT-cell activation2017
Abatacept 125 mg SC Q1W2017
Apremilast 30 mg PO BIDPDE42015
Tofacitinib 5 mg PO BIDJAK signalling pathway2018
  • BID, two times per day; BIW, twice weekly; IL, interleukin; IV, intravenously; JAK, Janus kinase; PDE, phosphodiesterase; PO, orally; PsA, psoriatic arthritis; QxW, every x weeks; SC, subcutaneously; TNF-α, tumour necrosis factor-α.